Y-mAbs Therapeutics, Inc. (YMAB) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-09-16

Y-mAbs Therapeutics, Inc. (YMAB) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every YMAB SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Y-mAbs Therapeutics, Inc. (YMAB)

SEC CIK	0001722964

Recent YMAB Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-09-16	Wedell-Wedellsborg Johan	Insider	J — Other acquisition / disposition	4.56M	$8.60	$39.21M	SEC
2025-09-16	HEALY JAMES	Insider	D — Derivative transaction	25.1K	—	—	SEC
2025-09-16	HEALY JAMES	Insider	J — Other acquisition / disposition	2.19M	$8.60	$18.87M	SEC
2025-09-16	Gad Thomas	CHIEF BUSINESS OFFICER	J — Other acquisition / disposition	67.7K	$8.60	$582K	SEC
2025-09-16	Gad Thomas	CHIEF BUSINESS OFFICER	J — Other acquisition / disposition	60.0K	$8.60	$516K	SEC
2025-09-16	Wedell-Wedellsborg Johan	Insider	J — Other acquisition / disposition	5.8K	$8.60	$50K	SEC
2025-09-16	Wedell-Wedellsborg Johan	Insider	D — Derivative transaction	25.1K	—	—	SEC
2025-09-16	HEALY JAMES	Insider	J — Other acquisition / disposition	31.6K	$8.60	$272K	SEC
2025-09-16	GILL DAVID N	Insider	D — Derivative transaction	5.8K	$8.60	$50K	SEC
2025-09-16	GILL DAVID N	Insider	D — Derivative transaction	25.1K	—	—	SEC
2025-09-16	PFREUNDSCHUH PETER P.	EVP, CFO and Treasurer	D — Derivative transaction	77.8K	—	—	SEC
2025-09-16	Rossi Michael J	PRESIDENT CEO	J — Other acquisition / disposition	8.0K	$8.60	$69K	SEC
2025-09-16	Rossi Michael J	PRESIDENT CEO	D — Derivative transaction	129.1K	—	—	SEC
2025-09-16	LaRocca John	SVP, General Counsel Secry	D — Derivative transaction	21.5K	—	—	SEC
2025-09-16	WG Biotech ApS	Insider	J — Other acquisition / disposition	4.56M	$8.60	$39.21M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Y-mAbs Therapeutics, Inc. (YMAB). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-09-16 — Rossi Michael J (PRESIDENT CEO)
2025-09-16 — GILL DAVID N (Insider)
2025-09-16 — HEALY JAMES (Insider)
2025-09-16 — PFREUNDSCHUH PETER P. (EVP, CFO and Treasurer)
2025-09-16 — LaRocca John (SVP, General Counsel Secry)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in YMAB insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

YMAB Insider Trading — FAQ

What is the latest insider trade for YMAB?: Y-mAbs Therapeutics, Inc. (YMAB) had 0 insider filings in the last 90 days, with the most recent on 2025-09-16. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying YMAB stock?: 0 insider purchases of YMAB were filed in the last 90 days.
How many insiders are selling YMAB stock?: 0 insider sales of YMAB were filed in the last 90 days.
Where can I see YMAB SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every YMAB SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live YMAB dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.